Cargando…

(11)C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement

Multiple myeloma (MM) remains an essentially incurable hematologic malignancy originating from clonal plasma cells. This study evaluated the usefulness of the radiotracers (11)C-methionine (MET) and (18)F-2`-deoxy-2`-fluorodeoxyglucose (FDG) for staging and re-staging in MM. 43 patients with MM unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lapa, Constantin, Knop, Stefan, Schreder, Martin, Rudelius, Martina, Knott, Markus, Jörg, Gerhard, Samnick, Samuel, Herrmann, Ken, Buck, Andreas K., Einsele, Hermann, Lückerath, Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729773/ https://www.ncbi.nlm.nih.gov/pubmed/26877783 http://dx.doi.org/10.7150/thno.13921

Ejemplares similares

(11)C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma
por: Lückerath, Katharina, et al.
Publicado: (2015)

(11)C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions
por: Lapa, Constantin, et al.
Publicado: (2017)

(18)FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
por: Lapa, Constantin, et al.
Publicado: (2014)

Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology
por: Lückerath, Katharina, et al.
Publicado: (2013)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features
por: Zhou, Xiang, et al.
Publicado: (2020)

(18)F-FDG and (11)C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers
por: Morales-Lozano, Maria I, et al.
Publicado: (2020)

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
por: Philipp-Abbrederis, Kathrin, et al.
Publicado: (2015)

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
por: Lapa, Constantin, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Glioblastoma Multiforme—A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy?
por: Lapa, Constantin, et al.
Publicado: (2015)

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature
por: Danhof, Sophia, et al.
Publicado: (2015)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT
por: Zhou, Xiang, et al.
Publicado: (2020)

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma
por: Leich, Ellen, et al.
Publicado: (2021)

First Experience of (11)C-Methionine PET in Multiple Myeloma in Turkey
por: Özkan, Elgin, et al.
Publicado: (2022)

(68)Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with(18)F-FDG, calcium burden and risk factors
por: Li, Xiang, et al.
Publicado: (2012)

PET imaging of noradrenaline transporters in Parkinson’s disease: focus on scan time
por: Brumberg, Joachim, et al.
Publicado: (2018)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
por: Loda, Sophia, et al.
Publicado: (2019)

Is the Image Quality of I-124-PET Impaired by an Automatic Correction of Prompt Gammas?
por: Preylowski, Veronika, et al.
Publicado: (2013)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
por: Hose, Dorothea, et al.
Publicado: (2020)

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
por: Evers, Marietheres, et al.
Publicado: (2023)

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
por: Kraus, Sabrina, et al.
Publicado: (2022)

(11)C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to (18)F-FDG PET/CT and Prognostic Value
por: Morales-Lozano, Maria I., et al.
Publicado: (2022)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study
por: Fischer, Julia, et al.
Publicado: (2022)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

STMO-11 Supratotal resection of Glioblastoma with Methionine PET
por: Ko, Ozaki, et al.
Publicado: (2020)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Comparison of (11)C-4′-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma
por: Okasaki, Momoko, et al.
Publicado: (2014)

[(18)F]FET-PET in children and adolescents with central nervous system tumors: does it support difficult clinical decision-making?
por: Kertels, Olivia, et al.
Publicado: (2023)

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
por: Kropff, Martin, et al.
Publicado: (2009)

Carbon-11-methionine and PET in evaluation of treatment response of breast cancer.
por: Huovinen, R., et al.
Publicado: (1993)

The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence
por: Xu, Weilin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5iqus0mf3sva156snc290ah7pm